Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

NCT01107665 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT01107665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01107665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
February 28, 2018
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii melanoma, stage iv melanoma, unresectable melanoma